Sort
51,593 grants matching “hepatitis”
Endocannabinoids And Energy Homeostasis
$2,308,469George Kunos · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2014 · AA
GENERAL CLINICAL RESEARCH CENTER
$2,306,787University Of Texas Sw Med Ctr/Dallas · M01 · FY2001 · RR
MULTICENTER AIDS COHORT STUDY
$2,306,709Howard Brown Health Center · U01 · FY2004 · AI
Molecular profiling and immunomodulatory interventions
$2,305,274University Of Pennsylvania · U01 · FY2004 · AI
NEUROAIDS: EFFECTS OF METHAMPHETAMINE AND HCV
$2,304,650Igor Grant · University Of California, San Diego · P01 · FY2006 · DA
Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos
$2,303,826Jorge R Kizer · Northern California Institute/Res/Edu · R01 · FY2020 · HL
Role of hypernutrition and metabolic stress in non-alcoholic steatohepatitis (NASH) driven hepatocellular carcinoma (HCC)
$2,302,833Randal J. Kaufman · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2025 · CA
Tele-Harm Reduction for Rapid Initiation of Antiretrovirals in People who Inject Drugs: a Randomized Controlled Trial
$2,302,500Hansel Emory Tookes · University Of Miami School Of Medicine · DP2 · FY2021 · DA
Characterization of the Fetal Primate Epigenome and Metabolome Under In Utero
$2,302,500Kjersti Marie Aagaard-Tillery · Baylor College Of Medicine · DP2 · FY2007 · OD
Molecular mechanisms and pathways of novel genomic loci regulating plasma lipids
$2,300,000Daniel James Rader · University Of Pennsylvania · RC2 · FY2010 · HL
RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - VALIDATION CENTER
$2,297,307Wilbur Lam · Emory University · N02 · FY2024 · HL
Synergies among inhibitory receptors in tolerance, cancer & antiviral immunity
$2,296,071Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · P01 · FY2021 · AI
NATURAL HISTORY OF HIV INFECTION IN WOMEN
$2,290,296Montefiore Medical Center (Bronx, Ny) · U01 · FY2001 · AI
Implementing and evaluating the impact of novel mobile harm reduction services on overdose among women who use drugs: The SHOUT study.
$2,289,649Susan Gail Sherman · Johns Hopkins University · R01 · FY2022 · DA
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
$2,288,273Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2025 · AG
Immunopathogenic Mechanisms of Human Immunodeficiency Virus (HIV) Disease
$2,284,358Irini Sereti · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Immune Pathophysiology of Aplastic Anemia and Immunosuppressive Treatments
$2,284,353Neal S Young · National Heart, Lung, And Blood Institute · ZIA · FY2010 · HL
Genetics of Brain Development
$2,281,396Maximilian Muenke · National Human Genome Research Institute · ZIA · FY2018 · HG
Hepatobiology and Toxicology COBRE
$2,279,140Craig J McClain · University Of Louisville · P20 · FY2017 · GM
Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos
$2,278,867Jorge R Kizer · Northern California Institute/Res/Edu · R01 · FY2021 · HL
B Cell Epitope Discovery: Dengue, Hepatitis C, Ebola, and Chikungunya viruses
$2,278,773Integral Molecular · N01 · FY2009 · AI
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection
$2,277,111Raymond T Chung · Massachusetts General Hospital · U19 · FY2015 · AI
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection
$2,277,111Raymond T Chung · Massachusetts General Hospital · U19 · FY2018 · AI
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection
$2,277,111Raymond T Chung · Massachusetts General Hospital · U19 · FY2016 · AI
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection
$2,277,110Raymond T Chung · Massachusetts General Hospital · U19 · FY2017 · AI